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Abstract
Tularemia, caused by the Gram-negative bacterium Francisella tularensis, is a severe, sometimes fatal disease. Interest in
tularemia has increased over the last decade due to its history as a biological weapon. In particular, development of novel
vaccines directed at protecting against pneumonic tularemia has been an important goal. Previous work has demonstrated
that, when delivered at very high inoculums, administration of live, highly attenuated strains of virulent F. tularensis can
protect against tularemia. However, lower vaccinating inoculums did not offer similar immunity. One concern of using live
vaccines is that the host may develop mild tularemia in response to infection and use of high inoculums may contribute to
this issue. Thus, generation of a live vaccine that can efficiently protect against tularemia when delivered in low numbers,
e.g. ,100 organisms, may address this concern. Herein we describe the ability of three defined, attenuated mutants of F.
tularensis SchuS4, deleted for FTT0369c, FTT1676, or FTT0369c and FTT1676, respectively, to engender protective immunity
against tularemia when delivered at concentrations of approximately 50 or fewer bacteria. Attenuated strains for use as
vaccines were selected by their inability to efficiently replicate in macrophages in vitro and impaired replication and
dissemination in vivo. Although all strains were defective for replication in vitro within macrophages, protective efficacy of
each attenuated mutant was correlated with their ability to modestly replicate and disseminate in the host. Finally, we
demonstrate the parenteral vaccination with these strains offered superior protection against pneumonic tularemia than
intranasal vaccination. Together our data provides proof of principle that low dose attenuated vaccines may be a viable goal
in development of novel vaccines directed against tularemia.
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Introduction
Francisella tularensis is a Gram-negative, facultative intracellular,
bacterium, whose species includes subspecies tularensis (also known
as Type A), subspecies holarctica (also known as Type B), and
subspecies mediasiatica. While subspecies tularensis is considered
highly virulent for humans [1,2], subspecies holarctica can cause
disease in humans that is not typically lethal [3], and subspecies
mediasiatica is considered avirulent in humans [4]. Additionally, the
F. novicida species is avirulent in the immunocompetent host [3]
and F. philomiragia is considered avirulent in humans [4].
Following inoculation by a variety of routes, both Type B and
Type A subspecies can cause the disease coined tularemia. There
are several forms of tularemia, dependent on the route by which
the host was exposed to organism. Among these, pneumonic
tularemia (acquired following inhalation of the bacterium)
mediated by Type A subspecies is widely considered the most
dangerous. This is, in part, due to the small numbers of organisms
required to cause disease, e.g. 15–20 bacteria [5]. Further, during
early stages of infection, when administration of antibiotic is ideal,
there are few pathological changes in the lung to signal disease [6].
Thus, diagnosis and execution of treatment may be delayed until
the organism has disseminated and caused wide spread, potentially
septic infection.
Although there are only approximately 100 cases of tularemia
per year in the United States and the incidence worldwide is
largely unknown, interest in tularemia has increased over the past
10 years (http://www.cdc.gov/tularemia/statistics/state.html).
This interest stems from development and use of virulent F.
tularensis as a biological weapon during the mid 20
th century [7]. In
response to development and history of weaponized F. tularensis,
there is renewed effort to develop novel vaccines that effectively
protect against tularemia, especially the pneumonic form.
To date, the most successful vaccine generated for protection
against tularemia was derived from a highly passaged strain of
subspecies holarctica [8]. The Live Vaccine Strain (LVS) has been
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subsp. tularensis in a wide variety of hosts, including humans
[5,8,9]. Unfortunately, a number of drawbacks associated with the
vaccine have precluded its licensure in the United States, among
which is the unknown mechanism of attenuation in LVS. Thus,
the risk of unexpected reversion to virulence is a possibility and
difficult to control. Furthermore, LVS failed to uniformly protect
against pneumonic tularemia in humans [10]. Finally, when
delivered in high concentrations, LVS can cause mild tularemia
and thus presents an undesirable sequela of vaccination [5,10].
One possible explanation for the inability of LVS to adequately
protect against infection with aerosolized Type A F. tularensis is that
key antigens required for protection against F. tularensis may not be
present in LVS. The failure of closely related pathogens to fail in
engendering complete protection against more virulent species has
been documented in the literature and could certainly hold true
for the poor protection offered by LVS against pneumonic
tularemia [11,12]. The complete genome of both LVS and a
representative strain of Type A, SchuS4, have been sequenced and
annotated. Although the genomes are very similar, there are
approximately 35 genes that encode different protein sequences
between LVS and SchuS4 [13]. Since the function of many of
these proteins is not defined, it is possible that they may represent
important protective antigens. Given these differences and
possibilities, there has been significant effort to develop defined,
attenuated strains of SchuS4 as vaccines with the hope that they
possess a more comprehensive array of protective antigens.
However, given the virulence of SchuS4, one attractive attribute
of vaccination with an attenuated strain would be that only small
numbers of bacteria are required to mediate effective protection
against challenge with wild type F. tularensis.
Previously, we described generation of two attenuated strains of
SchuS4 which resulted from single, targeted mutation of defined
genes, i.e. the FTT0369c and FTT1676 loci [14]. These genes
encode for proteins of unknown function and were identified via
transcriptional profiling of the bacterium during its intracellular
lifecycle. Both strains were attenuated for replication in primary
cells in vitro and their ability to cause lethal disease in vivo. The goal
of the current study was to determine if either or both of these
attenuated SchuS4 strains, in addition to a third mutant generated
by deleting both the FTT0369c and FTT1676 genes, could act as
vaccines against infection with wild type SchuS4. Here we
demonstrate that low vaccinating inoculums of F. tularensis
SchuS4DFTT0369c or F. tularensis SchuS4DFTT1676 efficiently
protected against both intradermal and intranasal infection with
wild type SchuS4. Combined deletion of the FTT0369c and
FTT1676 genes did not improve vaccine efficacy. Thus, our data
provide support for the generation of defined attenuated mutants
of Type A F. tularensis that provide protection against infection




Francisella tularensis subsp. tularensis strain SchuS4 was kindly
provided by Dr. Rick Lyons (Colorado State University, Ft.
Collins, CO). The in-frame single gene deletion mutants
SchuS4DFTT0369c and SchuS4DFTT1676 have been described
previously [14]. To generate a double DFTT0369cDFTT1676
mutant of Schu S4, electrocompetent SchuS4DFTT1676 were
prepared, electroporated with purified pJC84DFTT0369c plasmid
[14] and plated on kanamycin-containing (10 mg/ml) modified
Mueller-Hinton (MMH) plates as described [14], to select for
plasmid integration. Kanamycin-resistant colonies were subjected
to sucrose counter-selection as described [14], and sucrose-
resistant clones were analyzed for loss of kanamycin resistance
and allelic replacement within the correct chromosomal locus,
using primers JC614 (59-GCTTGAGGGTGCATTAG-39) and
JC615 (59-GGTATCTCAGGAGGTGTG-39) and primers JC610
(59-GCGAGATCTGGCTCGCTACGCTGTGACTGCCAAG-
39) and JC613 (59-GCGGTCGACGGTGTGTCTA-
GATGTGCTC-39), respectively [14]. Independent clones carry-
ing both in-frame deletions of the FTT1676 and FTT0369c loci
were isolated and used for further studies.
Bacteria used for in vivo infection were propagated as previously
described [15]. Briefly, all bacteria were cultured in modified
Mueller-Hinton broth (Mueller-Hinton broth supplemented with
CaCl2, MgCl2, 0.1% glucose, 0.025% ferric pyrophosphate and
2% Medium Enrichment [50% glucose, 167 mM L-cysteine-HCl,
68 mM L-glutamine, 3 mM adenine, 376 mM nicotinamide
adenine dinucleotide, 7 mM Vitamin B12, 217 mM thiamine
pyrophosphate, 160 mM guanine-HCl, 50 mM ferric nitrate,
95 mM aminobenzoic acid, 9 mM thiamine hydrocholride]) at
37uC with constant shaking overnight, aliquoted into 1 ml
samples, frozen at 280uC and thawed just prior to use as
previously described [16]. Frozen stocks were titered by enumer-
ating viable bacteria from serial dilutions plated on MMH agar as
previously described [17,18]. The number of viable bacteria in
frozen stock vials varied less than 1% over a 12 month period.
Mice
Female C57Bl/6J and Balb/c mice 6–8 weeks of age were
purchased from Jackson Laboratories (Bar Harbor, ME). Groups
of 5–10 mice were used in each experiment as indicated. Mice
were housed in BSL-2 and BSL-3 containment facilities at the
Rocky Mountain Laboratories and provided with food and water
ad libitum. All experiments with animals were conducted following
approved protocols and under the guidance of the ACUC at
Rocky Mountain Laboratories. Following infection with the
indicated strains of SchuS4, all animals were regularly monitored
for signs of illness. When signs of impending mortality were
observed, animals were immediately euthanized.
Generation and infection of bone marrow derived
macrophages
Bone marrow derived macrophages (BMMs) were propagated
from C57Bl/6J mice as previously described [14]. Bone marrow
cells were isolated from femurs of 6–10 week-old, C57BL/6J
female mice and differentiated into macrophages for 5 days at
37uC and 7% CO2, in 1 g/L glucose Dulbecco’s Modified Eagle
Medium (DMEM, Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Invitrogen), 10% L929-conditioned medium,
and 2 mM L-glutamine (cDMEM) in non-tissue culture-treated
Petri dishes. After 5 days, loosely adherent BMMs were washed
with PBS, harvested by incubation in chilled cation-free PBS
supplemented with 1 g/L D-glucose on ice for 10 min, resus-
pended in complete medium and replated in 24-well cell culture-
treated plates at a density of 1610
5 macrophages/well. BMMs
were further incubated at 37uC under 7% CO2 atmosphere for
48 h, replenishing with complete medium 24 h before infection.
For infections, bacteria grown on MMH agar plates for 3 days
were resuspended in MMH broth, diluted in complete medium
and 0.5 ml were added to chilled BMMs at an appropriate
multiplicity of infection (MOI). Bacteria were centrifuged onto
macrophages at 4006 g for 10 min at 4uC, and infected BMMs
incubated for 20 min at 37uC under 7% CO2 atmosphere
including an initial, rapid warm-up in a 37uC water bath to
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times with DMEM to remove extracellular bacteria, incubated for
40 min in complete medium, and then for an additional 60 min in
cDMEM containing 100 mg/ml gentamicin to kill extracellular
bacteria. Thereafter infected BMMs were incubated in gentami-
cin-free medium until processing.
To quantify intracellular colony forming units (CFUs), BMMs
(1610
5/well) were infected as described above, washed 3 times
with sterile PBS then lysed with 1 ml of sterile deionized water for
3 min at room temperature, followed by repeated pipetting to
complete lysis. Serial dilutions of the lysates were immediately
plated onto MMH agar plates. Plates were incubated for 3 days at
37uC under 7% CO2 before enumeration of colony forming units
(CFUs). The number of viable intracellular bacteria per well was
determined in triplicate for each condition and at least 2
independent experiments were performed.
Infection of mice
Balb/c mice were intranasally (10 CFU) or intradermally
(50 CFU) infected with F. tularensis strain SchuS4, DFTT0369c,
DFTT1676, or DFTT0369cDFTT1676 as previously described
[14,15]. In additional experiments animals were challenged with
the indicated doses of F. tularensis DFTT0369c SchuS4 intrader-
mally. Briefly, mice were anesthetized with a single intraperitoneal
injection of 12.5 mg/ml ketamine+3.8 mg/ml xylazine immedi-
ately prior to infection. For intranasal infections, bacteria were
diluted in PBS to the indicated inocula and were administered in a
total volume of 25 ml alternating between nares. For intradermal
infection, bacteria were diluted in PBS to the indicated inocula
and administered between the dermal sheets of the ear using a
30G needle and 300 cc syringe in a total volume of 10 ml. All
inocula were plated on MMH agar and incubated at 37uC/7%
CO2 for 48 hours to determine actual dose administered to the
animal.
Assessment of bacterial loads
Bacterial loads in target organs were determined as previously
described [15]. Briefly, the indicated tissues were aseptically
collected and placed in sterile PBS. Organs were immediately
homogenized by grinding tissues through a sterile S/S Type 304
#60 wire mesh screen (Billeville Wire Cloth Co., Cedar Grove,
New Jersey) using a 3 ml syringe plunger. Screens were rinsed with
approximately 0.5 ml PBS and the resulting homogenate was
immediately serially diluted in PBS. Dilutions of homogenate were
plated on MMH agar and incubated at 37uC/7% CO2 for 48–
72 hours and individual colonies were enumerated.
Statistical Analysis
Significance in survival between groups was determined using
Mantel-Cox (log-rank) analysis with significance set at p,0.05.
Significant difference in bacterial numbers in tissues among groups
of animals was determined using one way ANOVA followed by
Bonferroni’s post-test with significance set at p,0.05. LD50 was
determined using the Spearman-Karber method [19].
Results
Infectivity and replication of Schu S4DFTT0369 and Schu
S4DFTT1676 in vivo
Numerous studies have established the importance of intracel-
lular proliferation in the virulence of various subspecies and strains
of Francisella tularensis [14,20–27]. Recently, we identified two
genetic loci (FTT0369c and FTT1676) that were induced during
the intracellular cycle of the virulent strain SchuS4 and required
for intracellular proliferation [14]. Individual deletion of these loci
in SchuS4 generated mutant strains that were attenuated in mice
[14]. Given their attenuation in vivo, we sought to examine whether
inoculation with these mutants resulted in productive infection or
if the mutant strains were immediately eradicated at the site of
infection. Mice were infected intradermally or intranasally with a
target inoculum of 50 or 10 CFU, respectively. Consistent with
our previous observations [14], 95% and 80% of mice infected
intradermally with either DFTT0369c or DFTT1676 survived
infection, respectively (Figure 1B). Similarly, 95% of animals
receiving DFTT0369c intranasally and 90% of mice intranasally
infected with DFTT1676 survived infection (Figure 1C and [14]).
We next assessed bacterial replication and dissemination from
the site of infection to peripheral organs. Following intradermal
infection, replication of both DFTT0369c and DFTT1676 was
detected in the ear tissue. As expected, numbers of DFTT0369c
and DFTT1676 retrieved from the ear were significantly less than
those found in animals infected with wild type SchuS4 (Figure 2A).
Similarly, we isolated significantly fewer numbers of DFTT0369c
and DFTT1676 compared to wild type SchuS4 from both the
draining lymph node and spleen of intradermally infected animals
(Figure 2A). In the ear, DFTT0369c and DFTT1676 underwent
replication up to day 5 or 7 of infection, respectively. Neither
mutant was detected in the ear after day 10 of infection (Figure 2A).
Clearance of DFTT0369c and DFTT1676 bacteria from periph-
eral organs was obvious after day 7 of infection (Figure 2A).
We also assessed replication and dissemination following
intranasal infection. Similar to intradermal infection, significantly
fewer bacteria were retrieved from the lungs of mice infected with
either DFTT0369c or DFTT1676 compared to animals infected
with wild type SchuS4 on day 3 and 4 of infection (Figure 2B).
Dissemination of DFTT0369c and DFTT1676 to liver and spleen
was delayed in comparison to wild type SchuS4. However, once
bacteria arrived at these tissues they replicated to similar levels as
those observed on day 3 of infection in animals infected with wild
type SchuS4 (Figure 2B). Signs of control of replication of
DFTT0369c and DFTT1676 were apparent by day 10 after
infection in each tissue and all bacteria were cleared by day 30
(Figure 2B).
F. tularensis DFTT0369c and DFTT1676 mutants protect
against intranasal and intradermal SchuS4 infection
We next determined if animals exposed to low doses of either
DFTT0369c or DFTT1676 mutants that survived and cleared
infection were protected against secondary challenge with wild
type SchuS4. Previous studies have shown that intranasal
immunization offers superior protection compared to parenteral
routes, intradermal or subcutaneous [28,29]. Thus, we first
examined the ability of mice initially infected intranasally with
attenuated SchuS4 strains to survive secondary intranasal or
intradermal infection with wild type SchuS4. Mutant strain
DFTT0369c offered the best protection against wild type SchuS4
infection. Specifically, significantly more animals previously
exposed to DFTT0369c bacteria survived intranasal infection
with SchuS4 compared to mice first challenged with DFTT1676
bacteria, 80% survival versus 50% survival, respectively
(Figure 3A). Similarly, intranasal inoculation with DFTT0369c
organisms resulted in significantly greater protection against
intradermal challenge with SchuS4 compared to mice previously
infected with DFTT1676. Specifically, 50% of animals vaccinated
with DFTT0369c survived challenge with wild type SchuS4
compared to only 25% surviving animals vaccinated with
DFTT1676 (Figure 3B). Initially, this suggested that challenge
via the same route of vaccination may be required for optimal
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protection against SchuS4 infection compared to the DFTT1676
strain.
We next assessed protection in mice that were first challenged
with attenuated strains of SchuS4 intradermally. Regardless of the
route of challenge with wild type SchuS4, more animals that were
challenged intradermally with attenuated strains of SchuS4
survived infection compared to those that received attenuated
SchuS4 intranasally (Figure 3). Specifically, significantly greater
numbers of animals, i.e. 100%, exposed to either DFTT0369c or
DFTT1676 bacteria intradermally, were protected against wild
type SchuS4 infection when delivered via the same route
compared to naı ¨ve controls (Figure 3D). Further, significantly
more mice inoculated intradermally with DFTT0369c or
DFTT1676 bacteria were protected from an intranasal challenge
with wild type SchuS4 compared to naı ¨ve controls, i.e. 90% and
100%, respectively (Figure 3C). Thus, low dose intradermal
vaccination with either attenuated strains of SchuS4 efficiently
protected mice against both intranasal and intradermal infection
with wild type SchuS4.
Effect of the combination of the DFTT0369c and
DFTT1676 mutations on in vitro infection
Although both mutant strains offered protection against
infection with wild type SchuS4, at least one mutant (DFTT1676)
caused a lethal infection in 20% of inoculated mice (Figure 1B).
Thus, we hypothesized that a strain of SchuS4 deleted for both
FTT0369c and FTT1676 genes may be more attenuated in vivo,
but would still engender protection against infection with wild type
SchuS4. To this end, we generated a double deletion mutant of
both FTT0369c and FTT1676 loci and evaluated its ability to
infect macrophages and replicate intracellularly in vitro. Compared
to the parental SchuS4 strain, which grew by 3 orders of
magnitude within BMMs over a 24 h time frame, intracellular
viable numbers of the double mutant
SchuS4DFTT0369cDFTT1676 did not significantly increase
during the first 16 h pi, and even decreased afterwards, similar
to both single deletion mutants (Figure 1A). The double mutant
did not show a stronger intracellular defect than the single deletion
mutants, indicating that inactivation of these two genes does not
have an additive effect within macrophages (Figure 1A).
Virulence, replication and dissemination of the
SchuS4DFTT0369cDFTT1676 in vivo
We next assessed whether the DFTT0369cDFTT1676 mutant
was attenuated in vivo. All mice survived low dose infection with
DFTT0369cDFTT1676 regardless of the route of inoculation
(Figure 1B–C). Given this apparent attenuation, we next
determined if the DFTT0369cDFTT1676 mutant underwent
replication and/or dissemination following intradermal and
intranasal infection.
In contrast to DFTT0369c and DFTT1676 mutants, we were
unable to retrieve DFTT0369c DFTT1676 bacteria from the ears
of intradermally infected animals (Figure 2A). However, assess-
ment of the draining lymph node and spleen revealed dissemina-
tion and replication of the double mutant in each peripheral
Figure 1. In vitro and in vivo attenuation of SchuS4DFTT0369c, DFTT1676 and DFTT0369cDFTT1676 mutants. (A) Intracellular growth of
F. tularensis SchuS4, DFTT0369c, DFTT1676 and DFTT0369cDFTT1676 strains in murine BMMs derived from C57Bl/6J mice. BMMs were infected with
either strains, as described in the Materials and Methods section, and intracellular viable bacteria were enumerated at the indicated times points after
infection. Values are means 6 SD of a representative experiment performed in triplicate. Data is representative of 2 experiments of similar design. (B–
C) Balb/c mice (n=5–10/group) were infected intradermally (B) or intranasally (C) with approximately 50 CFU or 10 CFU, respectively, of the indicated
strains of F. tularensis SchuS4. Mice were regularly monitored up to 30 days after infection and euthanized at the first sign of irreversible illness.
doi:10.1371/journal.pone.0037752.g001
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bacteria were significantly lower than either single mutant at day
3 and day 7 in the lymph node and spleen, respectively (Figure 2A).
Together this suggested that, although DFTT0369cDFTT1676
bacteria were less competent for replication following intradermal
infection compared to DFTT0369c or DFTT1676 strains, the
double mutant was not completely defective for replication in vivo.
Clearance of DFTT0369cDFTT1676 bacteria in the draining
lymph node occurred earlier than either single mutant with no
bacteria observed in this tissue by day 10 of infection. However,
control and clearance of DFTT0369cDFTT1676 bacteria in the
spleen was similar to that observed for infection mediated by either
single mutant (Figure 2A).
In contrast to our inability to detect replication of the
DFTT0369cDFTT1676 mutant at the site of infection following
intradermal infection, it was capable of limited replication in the
lung during the first three days of infection (Figure 2B). However,
DFTT0369cDFTT1676 were readily controlled thereafter and we
did not detect bacteria in the lung after this time point (Figure 2B).
We also observed transient and modest dissemination and/or
replication of the DFTT0369cDFTT1676 mutant to the liver and
spleen following intranasal infection with significantly fewer
numbers retrieved from these organs at each time point tested
compared to both DFTT0369c and DFTT1676 bacteria. Togeth-
er these data suggest that both DFTT0369c and DFTT1676 are
modestly attenuated in vivo, whereas the double mutant
DFTT0369cDFTT1676 is significantly impaired for replication
and dissemination compared to single mutant strains.
The SchuS4DFTT0369cDFTT1676 mutant engenders
minimal protection against intranasal and intradermal
SchuS4 infection
We next determined if animals exposed to low doses of
DFTT0369cDFTT1676 bacteria were protected against secondary
challenge with wild type SchuS4. Unlike animals inoculated with
single mutants, protection engendered by DFTT0369cDFTT1676
bacteria was very poor and significantly lower than animals
vaccinated with either SchuS4 single deletion mutant. Specifically,
only 10% of mice first challenged intranasally survived intranasal
infection with wild type SchuS4 (Figure 3A). Similarly, signifi-
cantly fewer mice (i.e. 30%) that were previously infected with
DFTT0369cDFTT1676 survived intradermal SchuS4 infection
(Figure 3B). Data with the single mutants suggested that
intradermal inoculation may provide superior protection against
wild type SchuS4 challenge. Thus, we next assessed protection
against SchuS4 challenge in mice previously inoculated with
DFTT0369cDFTT1676 bacteria intradermally. Similar to our
observation that previous intradermal infection provided greater
protection against SchuS4 challenge, 70% of animals receiving the
DFTT0369cDFTT1676 mutant survived secondary intradermal
infection with SchuS4 and 60% survived intranasal infection with
the wild type strain. However, despite this improved protection
compared to intranasal inoculation, the double mutant was not as
effective as either single mutant for protecting against wild type
SchuS4 (Figure 3).
Figure 2. In vivo proliferation and dissemination of SchuS4DFTT0369c, DFTT1676 and DFTT0369cDFTT1676 mutants following
parenteral or pulmonary inoculations. Balb/c mice (n=5–10/group) were infected intradermally (A) or intranasally (B) with approximately
50 CFU or 10 CFU, respectively, of the indicated strains of F. tularensis SchuS4. Mice were regularly monitored up to 30 days after infection and
euthanized at the first sign of irreversible illness. At the indicated time points, organs were harvested and assessed for bacterial burdens as described
in the materials and methods. Error bars represent SEM. Data is representative of two experiments of similar design. * indicates a p value,0.05
compared to SchuS4. ** indicates a p value,0.05 compared to all other groups. Asterisks colors refer to the strain tested for statistically significant
difference.
doi:10.1371/journal.pone.0037752.g002
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vivo
Although the ability of low doses of attenuated SchuS4 mutants
to protect against virulent challenge is an important observation,
there is a possibility that a modest increase in inoculating dose
would result in fulminant, lethal disease. Obviously, this would be
an undesirable feature for any vaccine. Regardless of route,
inoculation of mice with 50 CFU of the DFTT0369c mutant did
not result in any deaths. Furthermore, this strain offered the best
protection against challenge with wild type SchuS4 following
intranasal vaccination and similar protection following intrader-
mal vaccination compared to the other single deletion mutant
DFTT1676. This suggested that DFTT0369c may represent a
viable vaccine strain for protection against wild type SchuS4.
Thus, we next determined the LD50 of DFTT0369c and
protection engendered by this strain when delivered at doses
higher than 50 CFU. Significantly greater numbers of mice
challenged with approximately 5610
4 CFU DFTT0369c survived,
i.e. 100%, compared to all other doses tested (Figure 4A).
Similarly, challenge with approximately 5610
5 CFU DFTT0369c
resulted in 60% survival and significantly more living mice
compared to animals challenged with 1–3610
6 CFU DFTT0369c
(Figure 4A). Using the Karber method we calculated that that
LD50 of intradermal infection with DFTT0369c was approxi-
mately 6.3610
5 CFU.
We next determined if high dose vaccination with D FTT0369c
was capable of protecting animals against intranasal infection with
SchuS4. Similarly to results observed in mice that received
50 CFU DFTT0369c intradermally, 100% of animals vaccinated
intradermally with 5610
4 DFTT0369c survived intranasal infec-
tion with 50 CFU wild type SchuS4 (Figure 4B). However,
intradermal vaccination with 5610
4 CFU D FTT0369c failed to
protect animals against exposure to higher numbers (200 CFU) of
wild type SchuS4 (Figure 4C).
Discussion
The study presented herein demonstrated that inoculation of
low doses of defined, attenuated mutants of F. tularensis strain
SchuS4 could protect against parenteral and intranasal challenge
with fully virulent wild type SchuS4. Furthermore, we confirmed
that inoculation of higher doses of one attenuated mutant, i.e. up
to 3log10 higher, did not result in adverse events in the host and
offered a similar level of protection against intranasal challenge of
up to 50 CFU wild type SchuS4. Thus, our data suggest that use
of a defined, attenuated SchuS4 mutant may not require
inoculation of extremely high numbers of the vaccinating strain.
Rather, effective protection can be achieved with relatively low
doses of attenuated organisms. Furthermore, our data demonstrate
that increase in vaccinating inoculum does not correlate to
increased protection against wild type SchuS4 and suggests that
generation of protective immunity against tularemia requires
features that are independent of ‘‘antigen load’’.
There are a number of strategies for the generation of novel
vaccines directed against tularemia. Although LVS can offer some
Figure 3. Protective capability of SchuS4DFTT0369c, DFTT1676 and DFTT0369cDFTT1676 mutants against parenteral and
pulmonary challenge with wild type SchuS4. Balb/c mice (n=10/group) were infected intradermally or intranasally with approximately 50 CFU
or 10 CFU, respectively, of the indicated strains of F. tularensis SchuS4. Forty-five days after infection, mice were challenged with approximately
50 CFU or 10 CFU of wild type F. tularensis SchuS4 intradermally or intranasally, respectively. Mice were regularly monitored up to 30 days after
infection and euthanized at the first sign of irreversible illness. Data are representative of 2 experiments of similar design. *=p,0.05 compared to all
other groups. **=p,0.05 compared to naı ¨ve animals and mice vaccinated with DFTT0369cDFTT1676.
doi:10.1371/journal.pone.0037752.g003
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detraction of LVS for current use is the ill-defined nature of its
attenuation. Paired with a spontaneous ability to undergo a phase
shift which negatively affects its protective efficacy, LVS is no
longer a licensed vaccine for use against tularemia in the United
States [9]. In response to these undesirable attributes of LVS, new
efforts have been placed on developing defined, attenuated
mutants of homologous strain, i.e. F. tularensis subsp. tularensis,
which effectively protect against tularemia.
Several laboratories have reported success in generating defined
Type A F. tularensis mutants that can protect against challenge with
virulent F. tularensis. However, vaccination with these attenuated
strains was typically only successful against intradermal infection
with Type A F. tularensis with minimal to no protection against
aerosol/intranasal infection. For example, F. tularensis deletion
mutant DFTT0918 efficiently protected 100% of animals against
intradermal infection with wild type F. tularensis, but only around
30% of mice vaccinated with this strain survived aerosol infection
[30]. Similarly, a purine auxotroph mutant (F. tularensis DpurMCD)
successfully protected all mice from secondary parenteral infection
with wild type SchuS4, but failed to protect more than 14% of
animals against pneumonic tularemia [31].
There are two examples in which immunization with attenuated
Type A F. tularensis offered greater protection against challenge
with wild type strains compared to earlier reports. First,
vaccination with bacteria deleted of the gene encoding a
hypothetical lipoprotein (FTT1103) successfully protected against
intranasal challenge of wild type F. tularensis SchuS4 [32]. A later
report demonstrated that a single intradermal immunization with
F. tularensis DFTT0918DclpB could protect approximately 40% of
Balb/c mice from aerosol infection with fully virulent SchuS4 [33].
Similarly, in the report presented herein all three mutants offered
anywhere from 20–100% protection against intranasal or intra-
dermal challenge with 10–50 SchuS4 organisms, respectively
(Figure 3). However, it is important to note that successful
protection against SchuS4 utilizing the mutants discussed in the
current report was achieved with a single dose of approximately
50 CFU of the vaccinating strain. Furthermore, we also
established that animals inoculated with up to 5610
4 CFU of
SchuS4DFTT0369c did not succumb to disease following infection
and were readily protected against a low dose intranasal challenge
with wild type SchuS4. This suggests that a fairly wide range of
vaccinating doses may be used to establish equivalent protection.
In contrast, others have had to use anywhere from 10
5–10
8 CFU
of attenuated SchuS4 strains to achieve similar protection [30].
Interestingly, unlike other studies, vaccination via the same
route as infection with wild type SchuS4 was not required to
generate protective immunity. Rather, intradermal vaccination
with any of the three mutants elicited a superior protection against
both intradermal and intranasal challenge with SchuS4 compared
to animals that received attenuated strains via the intranasal route
(Figure 3). Thus, our data suggests that intranasal vaccination is
not required for protection against pneumonic tularemia. This is
in agreement with our and others earlier investigation with LVS
and attenuated F. tularensis mutants in which effective protection
following intranasal infection with SchuS4 was observed in mice
vaccinated subcutaneously [34,35]. Additionally, our data also
suggests that intranasal immunization with live bacteria did not
promote similar immune responses as those generated following
intradermal vaccination. This idea is in line with previous reports
from Woolard et al in which intranasal immunization with LVS
provoked fewer protective IFN-c producing T cells compared to
subcutaneous immunization [36].
Among the SchuS4 mutants tested in this study, we observed
differences in their ability to engender protective immunity.
Regardless of the route of vaccination the single mutants offered
Figure 4. LD50 of SchuS4DFTT0369c and protective efficacy following increased challenge dose of wild type SchuS4. (A) Balb/c mice
(n=10/group) were infected intradermally with the indicated number of F. tularensis DFTT0369c. Mice were regularly monitored for up to 45 days
after infection and euthanized at the first signs of irreversible illness. (B and C) Mice (n=10/group) were challenged with approximately 5610
4 CFU
intradermally. Forty-five days after infection mice were challenged intranasally with approximately 50 CFU (B) or 200 CFU (C) wild type SchuS4. Mice
were regularly monitored for up to 30 days after infection and euthanized at the first signs of irreversible illness. *=p,0.05 compared to all other
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to the DFTT0369cDFTT1676 double mutant. Early studies
suggested that viable, replicating organisms are required for
elicitation of protective immunity against F. tularensis, presumably
to allow full unveiling of protective antigens. Absence of bacterial
replication might explain lack of development of effective memory
immunity in studies in which killed bacteria were used as the
vaccinating agent [37]. Thus, one could speculate that the
differences in protection mediated by the attenuated strains of
SchuS4 used in this study could have been attributed to differential
infection and replication in vitro. However, all three mutants
exhibited similarly impaired intracellular replication within
macrophages in vitro (Figure 1A). By contrast, we found striking
differences in the ability of these mutants to establish infection in
vivo. While both DFTT0369c and DFTT1676 bacteria exhibited
similar replication at the site of infection (lung or ear) and
dissemination to and replication in peripheral organs (Figure 2),
the DFTT0369cDFTT1676 mutant underwent weak replication at
the site of infection and minimal dissemination to peripheral
organs (Figure 2). Thus, the failure of the DFTT0369DFTT1676
mutant to engender protection against wild type SchuS4 infection
similar to that observed using single mutants can be correlated
with its inability to replicate at the site of infection and/or
peripheral organs. Furthermore, we demonstrate that vaccination
with 5610
4 DFTT0369c resulted in similar numbers of mice
capable of surviving challenge with 50 CFU wild type SchuS4
compared to those that were vaccinated with only 50 CFU of the
DFTT0369c strain. However, animals vaccinated with 5610
4
DFTT0369c were not protected against infection with 200 CFU
wild type SchuS4. Thus, our data also demonstrate that increase in
‘‘antigen’’ during vaccination does not correlate to increased
protection. Rather, we suggest that specific, important, elements of
protective immunity are not elicited by the DFTT0369c mutant
and that this is independent of the vaccinating dose. Alternatively,
we have recently shown that animals which have survived
infection with wild type SchuS4 are not fully protected against
secondary challenge with the same strain [38]. This suggests that
wild type SchuS4 may possess an inherent ability to inhibit
development of effective adaptive immunity and that this feature
has not been altered in the single deletion mutants.
Importantly, our data also suggests that replication deficiency in
macrophages in vitro does not necessarily correlate with a lack of
infectivity in vivo, since both single mutants were capable of limited
proliferation at the site of infection and dissemination despite
being deficient for replication in macrophages. This is in
agreement with previous reports examining defined deletion
mutants of SchuS4 for infection of cells and virulence in vitro
and in vivo [39,40] and indicates that i) replication of Francisella
within macrophages is only a component of the bacterium’s ability
to proliferate within host tissues and disseminate to peripheral
organs and ii) other cell types or extracellular compartments likely
support bacterial proliferation.
When comparing protective efficacy of the single mutants used
in this study there was little difference between the strains when
immunization occurred via the intradermal route. However,
following intranasal vaccination, significantly more animals that
were first exposed to DFTT0369c bacteria survived intranasal
challenge with wild type organism compared to mice immunized
with the DFTT1676 strain. Since both bacteria had similar
patterns of replication and dissemination in vivo, these results may
suggest that the way in which the mutants interacted with the
immune system was different. Previously, it has been shown that
wild type strains of F. tularensis potently suppress both inflamma-
tion and developing T cell responses. For example, we and others
have observed that SchuS4 readily inhibits recruitment of
inflammatory cells and production of cytokines associated with
protective T cell response, e.g. IL-12 [16,39,41,42]. Furthermore,
it has also been reported that Francisella infection can result in
degradation of both Major Histocompatibility Complex II
(MHCII) and CD86 on the surface of antigen presenting cells
[43]. These receptors are critical for antigen presentation and
subsequent protective T cell responses directed against Francisella.
Therefore, it is possible that the increased protective efficacy
observed in mice immunized with DFTT0369c bacteria was partly
due to the inability of this mutant to effectively inhibit
inflammatory and/or T cell responses. In support of this
hypothesis, we have recently shown that DFTT0369c induced
secretion of IL-12p40 from primary dendritic cells, whereas
infection with wild type SchuS4 failed to do so [41]. Further
studies on the functions of the proteins encoded by the FTT0369c
and FTT1676 loci may reveal molecular basis for the different
protective efficacy of these mutants.
Together our data provide proof of principle that delivery of low
doses of live, attenuated vaccine derived from fully virulent Type A
F. tularensis subspecies can protect against challenge with virulent
homologous strains. Furthermore, our results support previous
work suggesting screening of mutants in multiple cell types for
competence in replication may be necessary for predicting
virulence and/or protective efficacy in vivo. Finally, these defined
attenuated mutants of SchuS4 may also be useful in defining the
role of specific host molecule, e.g. IL-12, or pathways that are
required for survival of tularemia.
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